Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sulfur hexafluoride - Bracco

Drug Profile

Sulfur hexafluoride - Bracco

Alternative Names: BRI; E-7210; LUMASON; Lumason; LUMASON UEA; SonoVue; sulfur hexafluoride lipid-type A microspheres; Sulphur hexafluoride

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bracco
  • Developer Bracco; Eisai Co Ltd
  • Class Contrast media; Fluorides; Inorganic sulfur compounds; Small molecules
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cerebrovascular disorders
  • Registered Breast disorders; Cardiovascular disorders; Liver disorders; Vesicoureteral reflux
  • Phase III Congenital heart defects

Most Recent Events

  • 30 Apr 2024 Bracco plans a phase III trial for Heart disorders (Diagnosis) in USA (IV, Injection) (NCT06400004)
  • 22 Feb 2021 The US FDA approves Sulfur hexafluoride for injectable suspension, for intravenous use or intravesical use in USA
  • 18 Feb 2021 No development reported - Phase-III for Coronary artery disease (Diagnosis) in USA, Germany, United Kingdom, Belgium (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top